AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
173.69
+3.53 (2.07%)
At close: Apr 22, 2025, 4:00 PM
174.83
+1.14 (0.66%)
After-hours: Apr 22, 2025, 5:22 PM EDT
AbbVie Revenue
In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth. AbbVie had revenue of $15.10B in the quarter ending December 31, 2024, with 5.60% growth.
Revenue (ttm)
$56.33B
Revenue Growth
+3.71%
P/S Ratio
5.34
Revenue / Employee
n/a
Employees
n/a
Market Cap
307.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 42.34B |
ABBV News
- 7 hours ago - Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - Barrons
- 1 day ago - LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed - FXEmpire
- 5 days ago - My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys - Seeking Alpha
- 8 days ago - Trump says US pharma tariffs coming in not-too-distant future - Reuters
- 11 days ago - Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages - CNBC
- 12 days ago - AbbVie Stock Up 9.2% After Key Signal - Benzinga
- 12 days ago - Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback - CNBC
- 13 days ago - AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade) - Seeking Alpha